Hyaluronic acid-based gels including lidocaine
AssigneeAllergan Industrie, SAS
InventorPierre F. Lebreton
Life of this patent
Estimating the term…
Abstract
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
Claims22
A method of filling in facial lines and depressions comprising administering to a patient a sterile dermal filler composition comprising hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE), and about 0.3% lidocaine by weight, wherein the method fills in facial lines and depressions without a substantial reduction in duration of effect as compared to a second composition comprising hyaluronic acid crosslinked with BDDE wherein the second composition does not include lidocaine but otherwise has the same composition as the first composition.
A method of restoring fat loss-related tissue volume comprising administering to a patient a sterile dermal filler composition comprising hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE), and about 0.3% lidocaine by weight, wherein the method restores fat loss-related tissue volume without a substantial reduction in duration of effect as compared to a second composition comprising hyaluronic acid crosslinked with BDDE wherein the second composition does not include lidocaine but otherwise has the same composition as the first composition.
A method of filling in facial lines and depressions comprising administering to a patient a sterile dermal filler composition comprising hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE), and about 0.3% lidocaine by weight, wherein the method fills in facial lines and depressions without a substantial reduction in the filling effect provided by the administration of a second composition comprising hyaluronic acid crosslinked with BDDE wherein the second composition does not include lidocaine but otherwise has the same composition as the first composition.
A method of restoring fat loss-related tissue volume comprising administering to a patient a sterile dermal filler composition comprising hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE), and about 0.3% lidocaine by weight, wherein the method restores fat loss-related tissue volume without a substantial reduction in the tissue volume-restoring effect provided by the administration of a second composition comprising hyaluronic acid crosslinked with BDDE wherein the second composition does not include lidocaine but otherwise has the same composition as the first composition.
Dependencies are inferred from the claim text.